| 2017-08-25 08:42:31|
ADMS 08:42 08/25 08/25/17
Adamas Pharmaceuticals price target raised to $33 from $29 at JMP Securities
JMP Securities analyst Jason Butler raised his price target on Adamas after the FDA approved its GOCOVRI drug as an adjunctive treatment for Parkinson's disease patients. The analyst says that the drug's label is "broad." He keeps an Outperform rating on the stock.